9688:HKEXZai Lab Ltd. Analysis

Zai Lab is trading at HK$14.69, just above its near‑term support of HK$14.08. The stock sits slightly above its 20‑day SMA and below the 200‑day SMA, indicating a neutral to slightly bearish long‑term bias. RSI 40.7 and a bearish MACD histogram reinforce short‑term caution. Volume increasing suggests growing market interest despite mixed earnings. Revenue down 6.5% to $99.6 million, driven by ZEJULA headwinds, yet EPS beat consensus, showing some pricing power. Margins remain deeply negative, with operating margin –69.6% and a gross margin of 8.1%, highlighting ongoing cost pressures.
Cash HK$661 million offsets debt HK$232 million (debt‑to‑equity 35%), providing a solid balance sheet. Valuation multiples are extreme – price‑to‑sales 36× and price‑to‑book 3.15 – but the market’s Extreme Greed sentiment and a 42% upside potential suggest the stock may be undervalued relative to its pipeline. Analyst consensus is a “strong buy” from 10 analysts, reinforcing the growth narrative. High 30‑day volatility (≈53%) and a historic max drawdown of 64% underline the risk. The biotech sector carries high regulatory and development risk, especially given the company’s China focus. Overall, the combination of cash strength, strategic collaborations, and upside potential supports a bullish stance for the coming years.